Vir Biotechnology saw the highest growth of 0.99% in patent filings in May and 2.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.42% and grants by 0.49%. GlobalData’s DataBook provides a comprehensive analysis of Vir Biotechnology‘s patent filings and grants. Buy the databook here.
Vir Biotechnology has been focused on protecting inventions in Australia(AU) with four publications in Q2 2024
The Australia(AU) Patent Office dominates the patent filings and grants with nearly 15% filings and 25% grants. The World Intellectual Property Organization(WIPO), Australia(AU), Israel(IL), and European Patent Office(EPO) patent Office are among the top ten patent offices where Vir Biotechnology is filings its patents. Among the top granted patent authorities, Vir Biotechnology has 25% of its grants in Australia(AU), 25% in United States(US) and 12% in Israel(IL).
Regeneron Pharmaceuticals and Amgen could be the strongest competitors for Vir Biotechnology
Patents related to rare diseases and Covid-19 lead Vir Biotechnology's portfolio
Vir Biotechnology has the highest number of patents in rare diseases followed by, Covid-19 and climate change. For rare diseases, nearly 23% of patents were filed and no patents were granted in Q2 2024.
Sepsis related patents lead Vir Biotechnology portfolio followed by zika virus infections, and influenzavirus a infections
Vir Biotechnology has highest number of patents in sepsis followed by zika virus infections, influenzavirus a infections, pneumonia, and severe acute respiratory syndrome (sars).
For comprehensive analysis of Vir Biotechnology's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.